Adult and cord blood endothelial progenitor cells have different gene expression profiles and immunogenic potential

Blood Transfusion

Volumn 12, Issue SUPPL.1, 2014, Pages

  Nuzzolo, Eugenia R ^a   Capodimonti, Sara ^a   Martini, Maurizio ^a   Iachininoto, Maria G ^a   Bianchi, Maria ^a   Cocomazzi, Alessandra ^a   Zini, Gina ^a   Leone, Giuseppe ^a   Larocca, Luigi M ^a   Teofili, Luciana ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cord blood; Endothelial progenitor cells; Vasculogenesis

Indexed keywords

ADULT; AGING; CELLS, CULTURED; COLONY-FORMING UNITS ASSAY; EMBRYONIC STEM CELLS; ENDOTHELIUM, VASCULAR; FETAL BLOOD; GENE EXPRESSION PROFILING; HL-60 CELLS; HLA ANTIGENS; HLA-D ANTIGENS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFANT, NEWBORN; INFLAMMATION; INTERFERON-GAMMA; MESENCHYMAL STROMAL CELLS; REAL-TIME POLYMERASE CHAIN REACTION; STEM CELLS; THROMBOPHILIA;

EID: 84893906485     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0042-13     Document Type: Article

References (37)

1. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis.Science 1997; 2759: 964-7
2. Kalka C, Masuda H, Takahashi T, et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic n neovascularization. Proc Natl Acad Sci USA 2000; 97:3422-7.
3. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 1584-95.
4. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004; 104: 2752-60.
5. Karantalis V, Balkan W, Schulman IH, et al. Cell-based therapy for prevention and reversal of myocardial remodeling. Am J Physiol Heart Circ Physiol. 2012; 303: H256-70.
6. Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg 2011; 53: 445-53.
7. Misra V, Ritchie MM, Stone LL, et al. Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy.Neurology 2012; 79 (13 Suppl 1): S207-12.
8. Sen S, McDonald SP, Coates PT, Bonder CS. Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease. Clin Sci (Lond) 2011; 120: 263-83.
9. Pelosi E, Castelli G, Testa U. Human umbilical cord is a unique and safe source of various types of stem cells suitable for treatment of haematological diseases and for regenerative medicine. Blood Cells Mol Dis 2012; 49: 20-8.
10. Lavergne M, Vanneaux V, Delmau C, et al. Cord bloodcirculating endothelial progenitors for treatment of vascular diseases.Cell Prolif 2011; 44 (Suppl 1): 44-7.
11. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/ progenitor cell principals. Blood 2007; 109: 1801-9.
12. Teofili L, Iachininoto MG, Capodimonti S, et al. Endothelial progenitor cell trafficking in human immunodeficiency virusinfected persons. AIDS 2010; 24: 2443-50.
13. Teofili L, Martini M, Iachininoto MG, et al. Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood 2011; 117: 2700-7.
14. Le Blanc K, Frassoni F, Ball LM, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graftversus- host disease: a phase II study. Lancet 2008; 371: 1579-86.
15. Ladhoff J, Fleischer B, Hara Y, et al. Immune privilege of endothelial cells differentiated from endothelial progenitor cells. Cardiovasc Res 2010; 88: 121-9.
16. Schwarz TM, Leicht SF, Radic T, et al. Vascular incorporation of endothelial colony-forming cells is essential for functional recovery of murine ischemic tissue following cell therapy. Arterioscler Thromb Vasc Biol 2012: 32: e13-21.
17. van Hinsbergh VW. Endothelium - role in regulation of coagulation and inflammation. Semin Immunopathol 2012; 34: 93-106.
18. Long EO. ICAM-1: getting a grip on leukocyte adhesion. J Immunol 2011; 86: 5021-3.
19. Kokubo T, Uchida H, Choi ET.Integrin alpha(v)beta(3) as a target in the prevention of neointimal hyperplasia. J Vasc Surg. 2007; 45(Suppl A): A33-8.
20. Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010; 87: 262-71.
21. De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med 2012; 44: 1-9.
22. Rider P, Carmi Y, Guttman O, et al. IL-1? and IL-1? recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 2011; 187: 4835-43.
23. Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007; 32: 332-41.
24. Loppnow H, Buerke M, Werdan K, Rose-John S. Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis J Cell Mol Med 2011; 15: 484-500.
25. Craige SM, Chen K, Pei Y, et al. NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 2011; 124: 731-40.
26. Bir SC, Xiong Y, Kevil CG, Luo J. Emerging role of PKA/ eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases. Cardiovasc Res 2012; 95: 7-18.
27. Luo GP, Ni B, Yang X, Wu YZ. von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol 2012; 128:158-69.
28. Rao RM, Yang L, Garcia-Cardena G, Luscinskas FW. Endothelial-dependent mechanisms of leukocyte recruitment to the vascular wall. Circ Res 2007; 101: 234-47.
29. Bernal A, San Martín N, Fernández M, et al. L-selectin and SDF-1 enhance the migration of mouse and human cardiac mesoangioblasts. Cell Death Differ 2012; 19: 345-55.
30. Holroyd EW, Simari RD. Interdependent biological systems, multi-functional molecules: the evolving role of tissue factor pathway inhibitor beyond anti-coagulation. Thromb Res 2010; 125 (Suppl 1): S57-59.
31. Iyer RP, Patterson NL, Fields GB, Lindsey ML. The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol 2012; 303: H919-30.
32. Wohner N. Role of cellular elements in thrombus formation and dissolution. Cardiovasc Hematol Agents Med Chem 2008; 6: 224-8.
33. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-506.
34. Buzzi M, Alviano F, Campioni D, et al. Umbilical cord blood CD34+ cell-derived progeny produces human leukocyte antigen-G molecules with immuno-modulatory functions. Human Immunol 2012; 73: 150-5.
35. Taflin C, Charron D, Glotz D, Mooney N. Immunological function of the endothelial cell within the setting of organ transplantation. Immunol Lett 2011; 139: 1-6.
36. Malliaras K, Li TS, Luthringer D, et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 2012; 125: 100-12.
37. Tseliou E, Pollan S, Malliaras K, et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol 2013; 61: 1108-19.